RhumbLine Advisers’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.6K Sell
1,107
-1,598
-59% -$35.7K ﹤0.01% 3853
2026
Q1
$71.2K Buy
2,705
+19
+0.7% +$2.39K ﹤0.01% 3517
2025
Q4
$666K Sell
2,686
-127
-5% -$29K ﹤0.01% 2482
2025
Q3
$592K Sell
2,813
-75
-3% -$13.2K ﹤0.01% 2578
2025
Q2
$284K Buy
+2,888
New +$252K ﹤0.01% 3017
2024
Q3
– Sell
-35
Closed -$2.55K – 4251
2024
Q2
$2.55K Sell
35
-8
-19% -$479 ﹤0.01% 4164
2024
Q1
$4.02K Hold
43
– – ﹤0.01% 4007
2023
Q4
$3.11K Hold
43
– – ﹤0.01% 4048
2023
Q3
$2.83K Sell
43
-55
-56% -$5.07K ﹤0.01% 4070
2023
Q2
$9.37K Sell
98
-969
-91% -$96.5K ﹤0.01% 3967
2023
Q1
$108K Buy
1,067
+17
+2% +$2.6K ﹤0.01% 2845
2022
Q4
$182K Buy
1,050
+26
+3% +$17.1K ﹤0.01% 2815
2022
Q3
$982K Buy
1,024
+103
+11% +$102K ﹤0.01% 2138
2022
Q2
$616K Sell
921
-141
-13% -$87.4K ﹤0.01% 2384
2022
Q1
$737K Sell
1,062
-79
-7% -$60.9K ﹤0.01% 2256
2021
Q4
$1.03M Buy
1,141
+9
+0.8% +$8.55K ﹤0.01% 2190
2021
Q3
$1.14M Buy
1,132
+40
+4% +$29.5K ﹤0.01% 2165
2021
Q2
$709K Buy
1,092
+114
+12% +$79.1K ﹤0.01% 2406
2021
Q1
$724K Sell
978
-51
-5% -$41.1K ﹤0.01% 2325
2020
Q4
$796K Buy
1,029
+125
+14% +$98.5K ﹤0.01% 2248
2020
Q3
$897K Sell
904
-72
-7% -$76.4K ﹤0.01% 2036
2020
Q2
$1.01M Buy
976
+222
+29% +$223K ﹤0.01% 2037
2020
Q1
$612K Buy
754
+38
+5% +$39.7K ﹤0.01% 2085
2019
Q4
$895K Buy
716
+28
+4% +$45.1K ﹤0.01% 2134
2019
Q3
$924K Buy
688
+393
+133% +$625K ﹤0.01% 2066
2019
Q2
$523K Buy
295
+139
+89% +$213K ﹤0.01% 2345
2019
Q1
$271K Buy
+156
New +$260K ﹤0.01% 2598

Other funds holding GOSS

RhumbLine Advisers's GOSS Position: Q2 2026 in Review

RhumbLine Advisers reduced its Gossamer Bio (GOSS) stake by 59% in Q2 2026, selling an estimated $35.7K and leaving 1,107 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3853.

RhumbLine Advisers first reported a position in GOSS in Q1 2019 and has held it in 27 quarters since. The position peaked at $1.14M in Q3 2021. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • RhumbLine Advisers held 1,107 shares of Gossamer Bio worth $14.6K as of Q2 2026.
  • RhumbLine Advisers sold 1,598 Gossamer Bio shares in Q2 2026, an estimated $35.7K.
  • Gossamer Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3853 holding.
  • RhumbLine Advisers first reported a position in Gossamer Bio in Q1 2019 and has held it in 27 quarters since.
  • RhumbLine Advisers's Gossamer Bio position peaked at $1.14M in Q3 2021.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.